Collectively, our results suggested that HR488B might be a promising candidate for CRC treatment and that targeting the E2F1/Rb/HDAC1 complex provides a rationale for future evaluation of HR488B as a potential drug in CRC. This evidence concerns the gene E2F1 and colorectal carcinoma.